Solid Biosciences Inc.
SLDB
$2.55
$0.031.19%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 25.95% | -- | -- | -- | 259.62% |
| Gross Profit | -25.95% | -- | -- | -- | -259.62% |
| SG&A Expenses | 33.97% | 22.50% | 16.80% | 7.97% | 147.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 79.19% | 52.21% | 3.28% | -16.13% | -7.38% |
| Operating Income | -79.19% | -52.21% | -3.28% | 16.13% | 7.38% |
| Income Before Tax | -109.47% | -55.98% | -1.80% | 19.18% | -34.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -109.47% | -55.98% | -1.80% | 19.18% | -34.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -109.47% | -55.98% | -1.80% | 19.18% | -34.22% |
| EBIT | -79.19% | -52.21% | -3.28% | 16.13% | 7.38% |
| EBITDA | -78.70% | -54.39% | -2.91% | 15.37% | 6.16% |
| EPS Basic | 0.76% | 24.51% | 51.10% | 58.55% | 23.82% |
| Normalized Basic EPS | 0.75% | 24.51% | 51.22% | 58.55% | 49.51% |
| EPS Diluted | 0.76% | 24.51% | 51.10% | 58.44% | 23.82% |
| Normalized Diluted EPS | 0.75% | 24.51% | 51.22% | 58.55% | 49.51% |
| Average Basic Shares Outstanding | 111.06% | 106.60% | 108.17% | 94.99% | 76.20% |
| Average Diluted Shares Outstanding | 111.06% | 106.60% | 108.17% | 94.99% | 76.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |